Tilray Brands, Inc.

TLRY

US88688T1007

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis business, Distribution business, Beverage alcohol business and Wellness business. The Cannabis business segment is engaged in the cultivation, production, distribution and sale of both medical and adult-use cannabis products. The Distribution business segment is engaged in the purchase and resale of pharmaceutical and wellness products. The Beverage alcohol business segment is engaged in the production, marketing and sale of beverage alcohol products. The Wellness business segment is engaged in the production, marketing and distribution of hemp-based food and other wellness products. The Company offers a broad portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, and Bake Sale, among others.

Sector

Pharmaceuticals

Calendar

2024-01-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

US Consumer Confused About Pot Rules, Tilray CEO Says

October 17, 2023 at 02:38 pm EDT

More Strategies

Ratings for Tilray Brands, Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.92USD

Average target price

2.735USD

Spread / Average Target

+42.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TILRAY BRANDS, INC.	-30.79%	1 402 M $
ELI LILLY AND COMPANY	+57.45%	538 B $
NOVO NORDISK A/S	+42.69%	430 B $
JOHNSON & JOHNSON	-12.59%	372 B $
ABBVIE INC.	-6.29%	264 B $
MERCK & CO., INC.	-6.14%	263 B $
ROCHE HOLDING AG	-12.46%	232 B $
NOVARTIS AG	+2.38%	198 B $
PFIZER, INC.	-44.29%	163 B $
AMGEN INC.	+3.53%	144 B $

Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 01:57:09 2023-12-11 pm EST			5-day change	1st Jan Change
1.865 ^USD	-2.86%		-9.62%	-30.79%

Dec. 06	Tilray Brands' Montauk Brewing Unit Expands Distribution into Florida	MT
Dec. 06	Tilray Brands, Inc. Through Its Wholly-Owned Licensed Subsidiaries, Aphria Inc, and Hexo Operations Inc., and Truss Beverages Company Limited Unveil Canadian Cannabis Lineup for the Holidays	CI

Tilray Brands' Montauk Brewing Unit Expands Distribution into Florida	Dec. 06	MT
Tilray Brands, Inc. Through Its Wholly-Owned Licensed Subsidiaries, Aphria Inc, and Hexo Operations Inc., and Truss Beverages Company Limited Unveil Canadian Cannabis Lineup for the Holidays	Dec. 06	CI
Toronto shares end lower as resource shares slide	Dec. 05	RE
IntelGenx Announcing Shareholder Approval of Financing Transactions	Nov. 28	MT
IntelGenx Brief: Announcing Shareholder Approval of Financing Transactions	Nov. 28	MT
Tilray Brands, Inc. Announces the Launch of Redecan?S New Redees ?Hemp?d? Pre-Rolls	Nov. 22	CI
Tilray Brief: Expanding Cannabis Beverage Portfolio With New THC, CBG and CBD Drink Innovations	Nov. 15	MT
Tilray Brands, Inc. Expands Cannabis Beverage Portfolio with New THC, CBG and CBD Drink Innovations by Top-Performing Canadian Brands	Nov. 15	CI
IntelGenx Receives OK to Conduct Montelukast VersaFilm Phase 2 Clinical Trial in Patients with Parkinson's Disease	Nov. 14	MT
TSX rebounds as higher oil prices fuel energy stocks	Nov. 13	RE
Good Supply Cannabis Launches 'Get Blitzen?d' Holiday Campaign and New Limited-Edition Products Across Canada	Nov. 09	CI
IntelGenx Announced Co-development and Commercialization of Cannabinoid-Infused VersaFilm Products with Tilray	Nov. 06	MT
IntelGenx Brief: Announciing Co-development and Commercialization of Cannabinoid-Infused VersaFilm Products with Tilray	Nov. 06	MT
MediPharm Labs Corp. Updated On $9 Million Settlement Agreement; All Tilray Shares Sold and Converted to Cash	Oct. 25	MT
US Consumer Confused About Pot Rules, Tilray CEO Says	Oct. 17	MT
Tilray Details a New Sustainability Campaign and Hemp Packaging Transition Across Its Canadian Cannabis Brand Good Supply	Oct. 17	MT
Tilray Medical Supports New Clinical Trial to Study Medical Cannabis in Glioblastoma Cancer Treatment	Oct. 16	MT
Tilray Brief: Tilray Medical Supports New Clinical Trial to Study Medical Cannabis in Glioblastoma Cancer Treatment	Oct. 16	MT
Tilray Brands' Montauk Releasing Major Wave Chaser Double India Pale Ale	Oct. 12	MT
TD Cowen Trims Tilray Brands Price Target to $2.50 From $3, Maintains Outperform Rating	Oct. 06	MT
TSX set for third weekly loss as robust jobs data fuel rate hike fears	Oct. 06	RE
Piper Sandler Reviews Tilray's Q1, Outlook	Oct. 05	MT
Social Buzz: Wallstreetbets Stocks Decline Premarket; Rivian Automotive Poised to Fall	Oct. 05	MT
Tilray Brands Q1 Loss Narrows to $0.10 Per Share, 15% Increase in Net Revenue	Oct. 04	MT
TSX Trims Earlier Losses, Now Down 33 Points, Energy The Biggest Decliner	Oct. 04	MT